View in EDS

A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.

Saved in:
Bibliographic Details
Title: A rare germline CDKN2A variant (47T>G; p16-L16R) predisposes carriers to pancreatic cancer by reducing cell cycle inhibition.
Authors: Horn IP; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Marks DL; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Koenig AN; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Hogenson TL; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Almada LL; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Goldstein LE; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Romecin Duran PA; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Vera R; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Vrabel AM; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Cui G; Division of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA., Rabe KG; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA., Bamlet WR; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA., Mer G; Division of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA., Sicotte H; Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota, USA., Zhang C; Division of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Li H; Division of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA., Petersen GM; Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA., Fernandez-Zapico ME; Division of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: fernandezzapico.martin@mayo.edu.
Source: The Journal of biological chemistry [J Biol Chem] 2021 Jan-Jun; Vol. 296, pp. 100634. Date of Electronic Publication: 2021 Apr 03.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Inc. on behalf of American Society for Biochemistry and Molecular Biology Country of Publication: United States NLM ID: 2985121R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1083-351X (Electronic) Linking ISSN: 00219258 NLM ISO Abbreviation: J Biol Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1083-351X
DOI:10.1016/j.jbc.2021.100634